Several mouse models as well as clinical studies were subsequently conducted, emphasizing the implication of the proinflammatory cytokine IL‐17 in the pathogenesis of psoriasis and showing the advantageous usage of IL‐17 antagonist or of its receptor blockade on clinical symptoms of psoriasis.66 Here, IL17A is linked to psoriasis.